Market Research Report
Ureter Cancer - Pipeline Review, H1 2018
|Published by||Global Markets Direct||Product code||247802|
|Published||Content info||154 Pages
|Ureter Cancer - Pipeline Review, H1 2018|
|Published: April 24, 2018||Content info: 154 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ureter Cancer - Pipeline Review, H1 2018, provides an overview of the Ureter Cancer (Oncology) pipeline landscape.
Ureter cancer or ureteral cancer is cancer of the ureter. Symptoms and signs of urethral cancer include bleeding from the urethra or blood in the urine, discharge from the urethra and enlarged lymph nodes in the groin area. Risk factors include smoking. Treatment includes surgery, chemotherapy and radiation therapy.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ureter Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Ureter Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ureter Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ureter Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 2, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 1 molecules, respectively.
Ureter Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.